NCT02520063 2026-02-06
Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer
University of Alabama at Birmingham
Phase 1/2 Completed
Clinical Trials
10 trialsNCT07002177 2026-01-07
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Forward Pharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT03284957 2025-11-24
AMEERA-1
Sanofi
Phase 1/2 Terminated
NCT00934895 2023-09-18
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
Rutgers, The State University of New Jersey
Phase 1/2 Terminated
NCT02871791 2022-08-29
Palbociclib With Everolimus + Exemestane In BC
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT03805399 2022-08-10
FUTURE
Fudan University
Phase 1/2 Unknown
NCT01031446 2018-08-31
Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Completed
NCT01939418 2017-10-03
Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer
National Cancer Center, Korea
Phase 1/2 Terminated
NCT00458237 2016-10-20
Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT00930475 2011-01-26
Everolimus (RAD001) and Carboplatin in Pretreated Metastatic Breast Cancer
Charite University, Berlin, Germany
Phase 1/2 Unknown